New appointments at Symphogen
This article was originally published in Scrip
Executive Summary
Symphogen, a private Danish biopharmaceutical company developing antibody therapeutics to treat cancer, and infectious and autoimmune diseases, has appointed Dr Ivan Horak chief scientific officer and medical officer and Gayle Mills chief business officer. Dr Horak joins from Enzon, where he was most recently president of R&D, having been chief scientific officer since 2005. Ms Mills had served as executive vice-president of business operations and chief business officer at Roxro Pharma for the past five years until the company's acquisition by Luitpold Pharmaceuticals, a subsidiary of Daiichi Sankyo.